Please login to the form below

Not currently logged in
Email:
Password:

Alexion

This page shows the latest Alexion news and features for those working in and with pharma, biotech and healthcare.

Apellis jumps as pegcetacoplan tops Alexion’s Soliris in PNH trial

Apellis jumps as pegcetacoplan tops Alexion’s Soliris in PNH trial

with C5 inhibitor Soliris and Alexion’s follow-up Ultomiris (ravulizumab), which brought in $990m and $90m respectively in the third quarter of 2019. ... the drug as opposed to a 1.5 g/dL decline with Alexion’s drug.

Latest news

More from news
Approximately 32 fully matching, plus 24 partially matching documents found.

Latest Intelligence

  • European biotech: a new generation of leaders emerges European biotech: a new generation of leaders emerges

    Previously chief exec of Boston-based biotech Syntimmune, (acquired by Alexion in November last year) Kress will be in post to oversee the filing of MOR208 later this year, and its

  • Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019 Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

    The forecast for 2023 sales is $1.97bn. Ultomiris (ravulizumab), from Alexion, treats paroxysmal nocturnal haemoglobinuria, a rare, potentially fatal blood disorder. ... It is a next- generation follow-on to Soliris, Alexion’s current PNH blockbuster

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Analysts predict peak sales of up to $3bn. 5. Ultomiris – Alexion’s follow-up to Soliris. ... Alexion is bracing for the patent expiry of its blockbuster Soliris (eculizumab), used to treat paroxysmal nocturnal haemoglobinuria (PNH) and myasthenia

  • European venture funding for the life science sector European venture funding for the life science sector

    Eli Lilly, Novartis and Alexion, should ensure a healthy M&A appetite going forward.

  • Deal Watch March 2017 Deal Watch March 2017

    In our Top 20 we have only three: Alexion in-licensed the lipid nanoparticle (LNP) technology from Arbutus Biopharma to use as a delivery technology for an mRNA rare disease product ... 90. Arbutus Biopharma. Alexion. Licence. Lipid Nanoparticle (LNP)

More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest appointments

  • New faces at Merus, Rubius Therapeutics and Titan Pharmaceuticals New faces at Merus, Rubius Therapeutics and Titan Pharmaceuticals

    Prior to CRISPR, he worked as head of translational medicine at Alexion Pharmaceuticals, and also served as chief medical officer of Taligen Therapeutics.

  • Abeona Therapeutics names CEO Abeona Therapeutics names CEO

    Carsten Thiel joins the biopharma from Alexion. Rare genetic disease focused biopharma Abeona Therapeutics has named its chief executive officer in the form of Carsten Thiel. ... Formerly serving as Alexion Pharmaceutical’s executive vice president and

  • Amryt Pharma appoints Jordi Casals as head of Europe Amryt Pharma appoints Jordi Casals as head of Europe

    Prior to this, he worked for eight years at Alexion Pharmaceuticals, latterly as vice president commercial operations, Western Europe.

  • Alexion Pharmaceuticals adds to its board Alexion Pharmaceuticals adds to its board

    Judith Reinsdorf recently worked at Johnson Controls. Alexion Pharmaceuticals has appointed Judith Reinsdorf to its board of directors following her role as executive vice president and general counsel of Johnson Controls. ... David Brennan, chairman of

  • Alexion appoints new senior VP for EMEAC region Alexion appoints new senior VP for EMEAC region

    Camilla Harder Hartvig will lead commercial activities from Zurich, Switzerland. Alexion Pharma has appointed Camilla Harder Hartvig as its senior vice president and head of its EMEAC region. ... Alexion’s global business, and look forward to

More from appointments
Approximately 3 fully matching, plus 8 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics